BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Amgen  Europe  B.V.  submitted  on  28 April 2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Vectibix,  through  the  centralised 
procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. 
The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  - 
complete and independent application 
The applicant applied for the following indication: treatment of metastatic carcinoma of the colon or 
rectum after failure of oxaliplatin- and/or irinotecan- containing chemotherapy regimens. 
Scientific Advice 
The applicant did not seek scientific advice at the CHMP. 
Licensing status 
Vectibix has been given first a Marketing Authorisation in United States of America for the treatment 
of Epidermal Growth Factor Receptor EGFR-expressing (EGFR Epidermal Growth Factor Receptor), 
metastatic  colorectal  carcinoma  with  disease  progression  on  or  following  fluoropyrimidine-, 
oxaliplatin-, and irinotecan-containing chemotherapy regimens in September 2006. 
A new application was filed in the following countries: Switzerland, Canada and Australia. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Frances Rotblat 
Co-Rapporteur:  Eva Skovlund 
Steps taken for the assessment of the product 
2. 
•  The application was received by the EMEA on 28 April 2006. 
•  The procedure started on 24 May 2006. 
•  The Rapporteur's first Assessment Report was circulated to all CHMP members on 7 August 2006 
(Annex 4.1). The Co-Rapporteur's first Assessment Report was circulated to all CHMP members 
on 11 August 2006 (Annex 4.2). 
•  During  the  meeting  on  19-21  September  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
applicant on 21 September 2006 (Annex 4.3). 
•  Inspections were carried out: 
•  Inspections of active Substance Manufacturers: 
At Amgen Inc. - Building 7 One Amgen Center Drive - Thousand Oaks, CA - USA 
Inspection  requested  by  CHMP  in  September  2006  meeting  and  performed  by  Dutch 
inspectorate on 25-27 October 2006. 
And at Amgen Inc. - 6701 Kaiser Drive - Fremont, CA - USA 
Inspection  requested  by  CHMP  in  September  2006  meeting  and  performed  by  Dutch 
inspectorate on 17-19 October 2006. 
•  Inspection of Finished Product Manufacturer: 
At Cardinal Health, PTS, LLC - 4757 Nexus Centre Drive - San Diego, CA - USA 
Inspection  requested  by  CHMP  in  September  2006  meeting  and  performed  by  Dutch 
inspectorate on 20-24 October 2006. 
•  The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
15 December 2006. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on 26 January 2007 (Annex 4.4). 
1/2 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
•  During the CHMP meeting on 19-22 February 2007, the CHMP agreed on a List of Outstanding 
Issues to be addressed in writing by the applicant (Annex 4.5). 
•  The  applicant  requested  an  oral  explanation  and  submitted  the  responses  to  the  CHMP  List  of 
Outstanding Issues on 19 March 2007. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Outstanding Issues to all CHMP members on 17 April 2007 (Annex 4.6). 
•  During  the  CHMP  meeting  on  23-26 April 2007,  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation. 
•  During the meeting on 21-24 May 2007, the CHMP, in the light of the overall data submitted and 
the scientific discussion within the Committee, issued a negative opinion for granting a Marketing 
Authorisation to Vectibix on 24 May 2007. 
1.3 
Steps taken for the re-examination procedure 
•  The applicant submitted written notice to the EMEA on 06 June 2007 to request a re-examination 
of the Vectibix CHMP opinion of 24 May 2007. 
•  During  its  meeting  on  19-21  June  2007,  the  CHMP  appointed  Dr  P.  Demolis  as  Rapporteur. 
Dr G. Calvo Rojas Co-Rapporteur. 
The  Rapporteur  and  Co-Rapporteur  appointed  by  the  CHMP  and  the  evaluation  teams  for  the 
re-examination were: 
Rapporteur:  Pierre Demolis 
Co-Rapporteur:  Gonzalo Calvo Rojas 
•  The  detailed  grounds  for  the  re-examination  request  were  submitted  by  the  applicant  on 
24 July 2007  (Appendix  2  of  Final  Opinion).  The  re-examination  procedure  started  on 
25 July 2007. 
•  During  its  meeting  on  17-19  July  2007,  the  CHMP  adopted  the  List  of  Questions  and  List  of 
Participants to the SAG on Oncology to be held on 05 September 2007. 
•  The  Rapporteur's  Assessment  Report  was  circulated  on  28 August 2007  (Annex  4.7).  The 
Co-Rapporteur's Assessment Report was circulated on 28 August 2007 (Annex 4.8). 
•  During  a  meeting  of  the  CHMP  Scientific  Advisory  Group  on Oncology  on  05  September  2007, 
experts  were  convened  to  consider  the  grounds  for  re-examination.  During  this  meeting  the 
applicant presented an oral explanation. A report of this meeting was forwarded to the CHMP on 
20 September 2007 (Annex 4.9). 
• 
During  the  meeting  on  18-20  September  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  final  Opinion 
recommending the granting of the conditional Marketing Authorisation for Vectibix. 
•  During  the  meeting  on  13-15 November 2007,  the  CHMP,  upon  the  European  Commission’s 
request  dated  12 November 2007,  adopted  a  revised CHMP  assessment  report  for  the  conditional 
Marketing Authorisation for Vectibix granted on 20 September 2007. 
2/2 
©EMEA 2007 
 
 
 
 
 
